CCO Infectious Disease Podcast

Key Decisions in HIV Care: Considering the Use of Proviral DNA Genotyping to Inform ART Choice

Episode Summary

Listen as John D. Baxter, MD, shares the latest data and recommendations for the use of proviral HIV DNA genotyping to inform ART choice for patients with significant ART experience.

Episode Notes

In this episode, John D. Baxter, MD, explores recommendations and data on the use of proviral DNA genotyping to inform antiretroviral therapy (ART) choice for patients who are treatment experienced.

Listen as he gives his perspectives on:

• US Department of Health and Human Services guideline recommendations on the use of proviral DNA genotyping
• US Department of Health and Human Services guideline recommendations and supporting data on switching ART with viral suppression and underlying drug resistance
• Study 380-4030 on outcomes with bictegravir- and dolutegravir-based ART in patients with preexisting nucleos(t)ide reverse-transcriptase inhibitor resistance
• The BRAAVE 2020 study on switching to bictegravir/emtricitabine/tenofovir alafenamide in Black persons with HIV, some of whom had baseline ART resistance
• Between-class ART switches with underlying resistance
• Susceptibility of tenofovir disoproxil fumarate and abacavir with thymidine analogue mutations

Presenter:

John D. Baxter, MD
Professor of Medicine
Division of Infectious Diseases
Department of Pathology
Cooper Medical School of Rowan University
Head, Division of Infectious Diseases
Cooper University Health Care
Camden, New Jersey

Follow along with the slides at:
https://bit.ly/3HmkSLc

See the entire program at: 
https://bit.ly/3fOl0XX